International Journal of Pharmacy and Pharmaceutical Research (IJPPR)
Volume 32, Issue 5, May 2026 ijppr.humanjournals.com ISSN: 2349-7203

Herbal vs Synthetic Anti-Arthritic Agents: A Comparative Review of Mechanisms and Preclinical Efficacy in Rheumatoid Arthritis

Miss. Shivani Tiwari[1], Prof (Dr.) Santosh Kumar Mishra[2], Mr. Ramji Mishra[2], Mr. Manvendra Singh[2]

Department of Pharmacology, Sagar college of Pharmacy, India.

Received: 27 March 2026 Revised: 22 April 2026 Accepted: 28 April 2026

ABSTRACT

Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disorder that primarily affects synovial joints, leading to inflammation, cartilage degradation, bone erosion, and progressive disability. Persistent inflammation ultimately leads to joint deformity and functional impairment, significantly affecting the quality of life of patients. Current management of RA largely depends on synthetic pharmacological agents such as nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and disease-modifying antirheumatic drugs (DMARDs), including both conventional and biologic therapies. While these agents are effective in controlling inflammation and slowing disease progression, their prolonged use is often associated with adverse effects such as gastrointestinal complications, hepatotoxicity, immunosuppression, and increased risk of infections. These limitations have encouraged the exploration of alternative therapeutic strategies.In recent years, herbal medicines have gained considerable attention due to their multi-targeted mechanisms, natural origin, and relatively safer profiles. Numerous plant-derived compounds, including flavonoids, alkaloids, terpenoids, and phenolic constituents, have demonstrated significant anti-inflammatory, immunomodulatory, and antioxidant properties in preclinical studies. These compounds can modulate key signaling pathways such as nuclear factor-kappa B (NF-κB), cyclooxygenase (COX), and cytokine networks, thereby contributing to their anti-arthritic effects. This review aims to provide a comprehensive comparison between herbal and synthetic anti-arthritic agents, focusing on their mechanisms of action and preclinical efficacy in rheumatoid arthritis. Understanding the advantages and limitations of both approaches may help in developing safer and more effective therapeutic strategies, including combination therapies.

Keywords: Rheumatoid arthritis, Herbal drugs, Synthetic drugs, Anti-arthritic activity, Preclinical studies, Cytokines, NF-κB, FCA model

1. INTRODUCTION

1.1 Overview of Rheumatoid Arthritis

1.1.1 Definition and epidemiology

Rheumatoid arthritis (RA) is a long-term, systemic autoimmune disorder that primarily targets synovial joints, resulting in chronic inflammation, progressive cartilage damage, and bone erosion. Unlike degenerative joint diseases, RA is characterized by an abnormal immune response in which the body's immune system mistakenly attacks its own joint tissues. This leads to synovial hyperplasia, infiltration of inflammatory cells, and the formation of pannus, a destructive tissue that gradually invades and damages joint structures. RA typically presents as a symmetrical polyarthritis, affecting small joints of the hands and feet in the early stages, and may later involve larger joints. In addition to joint involvement, it can also manifest with extra-articular complications such as cardiovascular disorders, pulmonary involvement, and fatigue. The disease follows a variable course, ranging from mild intermittent symptoms to severe, progressive disability if left untreated. Rheumatoid arthritis is one of the most common autoimmune inflammatory disorders worldwide, affecting approximately 0.5% to 1% of the global population. Its prevalence varies across different geographic regions, ethnic groups, and environmental conditions, with slightly higher rates reported in developed countries. In India, the estimated prevalence ranges from 0.3% to 0.7%, reflecting a significant public health burden.

International Journal of Pharmacy and Pharmaceutical Research (IJPPR)
Volume 32, Issue 5, May 2026 ijppr.humanjournals.com ISSN: 2349-7203



Fig 1: Rheumatoid Arthritis

The disease is more frequently observed in women than in men, with a female-to-male ratio of approximately 2:1 to 3:1. RA can occur at any age, but it most commonly develops between the ages of 30 and 60 years. Early onset cases may show a more aggressive disease course. Several risk factors contribute to the development of RA, including genetic susceptibility, particularly the presence of HLA-DRB1 gene alleles, as well as environmental triggers such as smoking, infections, and hormonal influences. Lifestyle factors and occupational exposures may also play a role in disease onset and progression. The chronic nature of RA and its associated disability contribute significantly to reduced quality of life and increased healthcare costs. Early diagnosis and timely intervention are crucial to minimize joint damage and improve long-term outcomes.

1.1.2 Etiology and risk factors

Rheumatoid arthritis (RA) is a multifactorial disease in which no single cause can fully explain its onset. Instead, it develops due to a complex interaction between genetic predisposition, environmental influences, and immune system abnormalities. The condition arises when immune tolerance is lost, leading to an inappropriate immune response against self-antigens, particularly within the synovial joints.

a) Genetic Factors

Genetic susceptibility plays a significant role in the development of RA. Specific alleles of the human leukocyte antigen (HLA) system, especially HLA-DRB1, are strongly associated with increased disease risk. These genetic variations influence antigen presentation and immune regulation, making individuals more prone to autoimmune reactions. Family history further supports the genetic link, as individuals with affected relatives have a higher likelihood of developing the disease.

b) Environmental Factors

Environmental triggers are believed to initiate or accelerate disease onset in genetically susceptible individuals. Among these, cigarette smoking is one of the most well-established risk factors, as it promotes inflammation and may induce modifications in proteins that trigger autoimmunity. Exposure to certain infections, air pollutants, and occupational hazards such as silica dust may also contribute to disease development by activating immune responses or enhancing inflammatory pathways.

c) Immunological Factors

RA is fundamentally an immune-mediated disorder. Dysregulation of immune cells, including T-cells, B-cells, and macrophages, leads to the production of autoantibodies such as rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPAs). These immune components drive chronic inflammation through the release of pro-inflammatory cytokines like TNF-α, IL-1β, and IL-6, ultimately resulting in joint damage and systemic manifestations.

d) Hormonal Influences

The higher prevalence of RA in women suggests a role for hormonal factors in disease pathogenesis. Fluctuations in estrogen and progesterone levels, particularly during pregnancy or menopause, may influence immune function and susceptibility to RA. Hormonal imbalance may therefore act as a modulating factor rather than a direct cause.

e) Lifestyle and Other Risk Factors

Certain lifestyle factors, including obesity, poor diet, and physical inactivity, may increase the risk or severity of RA by promoting systemic inflammation. Psychological stress has also been suggested to influence immune responses, potentially contributing to disease progression. Additionally, advancing age is associated with a higher likelihood of disease onset, possibly due to gradual immune system alterations.

1.1.3 Pathophysiology of RA

Rheumatoid arthritis (RA) is an autoimmune disorder characterized by chronic inflammation of the synovial joints. The disease begins with activation of immune cells such as T-lymphocytes, B-cells, and macrophages, which mistakenly recognize joint components as foreign. This leads to the production of autoantibodies, including rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPAs).

These immune reactions trigger the release of pro-inflammatory cytokines, particularly tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), and interleukin-6 (IL-6). These mediators promote synovial inflammation, increased vascular permeability, and infiltration of inflammatory cells into the joint space.

As the disease progresses, the synovial membrane becomes thickened and forms pannus, an abnormal invasive tissue that gradually destroys cartilage and bone. Additionally, oxidative stress and enzymatic degradation further contribute to joint damage. If untreated, this process leads to joint deformity, loss of function, and systemic complications.

1.2 Molecular Mechanisms Involved in RA

1.2.1 Role of cytokines (TNF-α, IL-1β, IL-6)

Cytokines are key regulators of inflammation and play a central role in the pathogenesis of rheumatoid arthritis. Among them, tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), and interleukin-6 (IL-6) are the principal pro-inflammatory mediators driving disease progression.

TNF-α acts as a master regulator of the inflammatory response. It stimulates the release of other cytokines, promotes leukocyte migration into synovial tissue, and increases the expression of adhesion molecules. TNF-α also contributes to joint destruction by activating osteoclasts, leading to bone erosion and cartilage damage.

IL-1β plays a major role in cartilage degradation. It enhances the production of matrix metalloproteinases (MMPs), which break down collagen and other structural components of cartilage. In addition, IL-1β inhibits cartilage repair mechanisms, further accelerating joint damage.

IL-6 contributes to both local joint inflammation and systemic manifestations of rheumatoid arthritis. It promotes B-cell activation and autoantibody production, while also stimulating the liver to produce acute-phase proteins. Elevated IL-6 levels are associated with symptoms such as fatigue, anemia, and overall disease severity.

1.2.2 Oxidative stress and free radicals

Oxidative stress plays an important role in the progression of rheumatoid arthritis by contributing to inflammation and joint damage. It occurs when there is an imbalance between the production of reactive oxygen species (ROS) and the body's antioxidant defense system. In RA, activated immune cells such as neutrophils and macrophages generate excessive amounts of free radicals, including superoxide anions, hydrogen peroxide, and hydroxyl radicals. These reactive species can damage cellular components such as lipids, proteins, and DNA within the synovial tissue. They also enhance the inflammatory response by activating signaling pathways and increasing the production of pro-inflammatory cytokines. In addition, oxidative stress promotes cartilage degradation and bone erosion by stimulating matrix-degrading enzymes. The body's natural antioxidant systems, including enzymes like superoxide dismutase and catalase, are often insufficient to counteract this increased oxidative burden in RA. Therefore, oxidative stress not

only contributes to disease progression but also represents an important therapeutic target, especially for antioxidant-rich herbal compounds.

1.2.3 Immune cell activation (T-cells, B-cells, macrophages)

Activation of immune cells is a central event in the pathogenesis of rheumatoid arthritis, leading to sustained inflammation and joint destruction. In RA, autoreactive T-cells become activated after recognizing self-antigens presented by antigen-presenting cells. These T-cells release pro-inflammatory cytokines and further stimulate other immune cells, amplifying the inflammatory response within the synovial tissue. B-cells contribute to disease progression by producing autoantibodies such as rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPAs). These autoantibodies form immune complexes that deposit in the joints, triggering complement activation and enhancing inflammation. B-cells also function as antigen-presenting cells and secrete cytokines, further promoting immune activation. Macrophages are major effector cells in RA and are abundant in inflamed synovial tissue. Once activated, they release large amounts of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6, which drive synovial inflammation and tissue damage. Macrophages also produce enzymes that degrade cartilage and stimulate osteoclast activity, leading to bone erosion. The interaction between T-cells, B-cells, and macrophages creates a self-perpetuating inflammatory cycle, resulting in chronic joint damage and progression of rheumatoid arthritis.

2. Synthetic Anti-Arthritic Agents

2.1 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used in the management of rheumatoid arthritis for the relief of pain, inflammation, and stiffness. These agents provide rapid symptomatic improvement but do not alter the underlying disease progression or prevent joint damage. The primary mechanism of NSAIDs involves the inhibition of cyclooxygenase (COX) enzymes, particularly COX-1 and COX-2, which are responsible for the synthesis of prostaglandins. Prostaglandins play a key role in mediating inflammation, pain, and fever. By reducing prostaglandin production, NSAIDs effectively decrease inflammation and alleviate pain associated with RA.

NSAIDs are broadly classified into non-selective inhibitors (such as ibuprofen, diclofenac, and aspirin) and selective COX-2 inhibitors (such as celecoxib). Non-selective NSAIDs inhibit both COX-1 and COX-2 enzymes, while selective inhibitors primarily target COX-2, which is more directly involved in inflammation. This selectivity helps reduce gastrointestinal side effects associated with COX-1 inhibition. Despite their effectiveness in symptom control, long-term use of NSAIDs is associated with adverse effects, including gastrointestinal irritation, ulceration, renal impairment, and increased cardiovascular risk. Therefore, NSAIDs are typically used as supportive therapy in combination with disease-modifying agents rather than as standalone treatment.

2.2 Corticosteroids

Corticosteroids are potent anti-inflammatory and immunosuppressive agents used in the management of rheumatoid arthritis for rapid control of inflammation and acute disease flares. They are particularly useful in reducing joint swelling, pain, and stiffness, especially during the early stages or exacerbations of the disease. The mechanism of action of corticosteroids involves the inhibition of inflammatory gene expression and suppression of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6. They also reduce leukocyte migration to inflamed tissues and stabilize lysosomal membranes, thereby limiting tissue damage.

Commonly used corticosteroids include prednisone and dexamethasone, which may be administered orally, intravenously, or through intra-articular injections depending on disease severity. Despite their strong therapeutic effects, long-term use of corticosteroids is associated with significant adverse effects, including osteoporosis, weight gain, hypertension, hyperglycemia, and increased susceptibility to infections. Therefore, they are generally prescribed at the lowest effective dose for the shortest possible duration, often as a bridging therapy alongside disease-modifying drugs.

2.3 Conventional DMARDs (e.g., Methotrexate)

Conventional disease-modifying antirheumatic drugs (DMARDs) are the cornerstone of rheumatoid arthritis management, as they not only reduce symptoms but also slow or halt disease progression and joint destruction. Unlike NSAIDs and corticosteroids, these agents target the underlying immune mechanisms responsible for chronic inflammation. Among conventional DMARDs, methotrexate is considered the first-line therapy due to its well-established efficacy and safety profile. It exerts its effect primarily by inhibiting dihydrofolate reductase, leading to reduced DNA synthesis in rapidly dividing immune cells. In addition, methotrexate increases extracellular adenosine levels, which contributes to its anti-inflammatory and immunosuppressive actions.

Other commonly used conventional DMARDs include sulfasalazine, leflunomide, and hydroxychloroquine. These drugs act through different mechanisms, such as inhibition of lymphocyte proliferation, suppression of cytokine production, and modulation of immune responses. Although conventional DMARDs are effective in controlling disease activity, they may take several weeks to months to produce noticeable clinical benefits. Long-term use can also be associated with adverse effects such as hepatotoxicity, bone marrow suppression, and gastrointestinal disturbances, requiring regular monitoring of patients. Conventional DMARDs remain a fundamental component of RA therapy and are often used alone or in combination with other agents to achieve optimal disease control.

2.4 Biologic DMARDs (TNF inhibitors, monoclonal antibodies)

Biologic disease-modifying antirheumatic drugs (biologic DMARDs) are advanced therapies designed to specifically target key molecules involved in the inflammatory process of rheumatoid arthritis. These agents are typically used in patients who show an inadequate response to conventional DMARDs and have significantly improved disease outcomes. One of the most important classes of biologics includes TNF inhibitors, such as etanercept, infliximab, and adalimumab. These agents act by directly binding to tumor necrosis factor-alpha (TNF-α), thereby preventing it from interacting with its receptors. This inhibition reduces inflammation, decreases immune cell activation, and slows joint destruction.

In addition to TNF inhibitors, several monoclonal antibodies target other inflammatory mediators. For example, tocilizumab inhibits the interleukin-6 (IL-6) receptor, while rituximab targets CD20-positive B-cells, reducing autoantibody production. Another agent, abatacept, modulates T-cell activation by interfering with co-stimulatory signals required for immune response. Biologic DMARDs are highly effective in controlling disease activity and preventing structural damage; however, they are associated with certain limitations. These include high cost, requirement for parenteral administration, and an increased risk of infections due to immunosuppression. Careful patient monitoring is therefore essential during therapy.

2.5 Mechanism of Action of Synthetic Drugs

Synthetic anti-arthritic drugs act by targeting key pathways involved in inflammation and immune activation in rheumatoid arthritis. Different classes of drugs exert their effects through distinct but complementary mechanisms. Nonsteroidal anti-inflammatory drugs (NSAIDs) reduce inflammation by inhibiting cyclooxygenase (COX) enzymes, thereby decreasing prostaglandin synthesis. Corticosteroids suppress the expression of inflammatory genes and reduce the production of pro-inflammatory cytokines, leading to rapid control of inflammation.

Conventional DMARDs, such as methotrexate, act by inhibiting the proliferation of immune cells and modulating cytokine production, which helps slow disease progression. Biologic DMARDs provide more targeted effects by blocking specific molecules involved in the inflammatory cascade, such as TNF-α, IL-6, or immune cell receptors.

Table 1: Limitations and Adverse Effects

Drug Class	Limitations	Adverse Effects
NSAIDs	Provide only symptomatic relief; do not prevent disease progression; long-term use required	Gastric irritation, peptic ulcers, gastrointestinal bleeding, renal impairment, increased cardiovascular risk
Corticosteroids	Suitable mainly for short-term use; risk of dependency; not ideal for long-term therapy	Osteoporosis, weight gain, hypertension, hyperglycemia, adrenal suppression, increased infection risk
Conventional DMARDs	Slow onset of action; require regular monitoring; variable patient response	Hepatotoxicity, bone marrow suppression, gastrointestinal disturbances, oral ulcers, pulmonary toxicity
Biologic DMARDs	High cost; require parenteral administration; not accessible to all patients	Increased susceptibility to infections (e.g., tuberculosis), infusion reactions, immunogenicity, possible malignancy risk
Targeted Synthetic DMARDs (e.g., JAK inhibitors)	Limited long-term safety data; careful dose monitoring required	Risk of infections, thrombosis, lipid abnormalities, liver enzyme elevation

International Journal of Pharmacy and Pharmaceutical Research (IJPPR)
Volume 32, Issue 5, May 2026 ijppr.humanjournals.com ISSN: 2349-7203

3. Herbal Anti-Arthritic Agents

3.1 Introduction to Herbal Medicine in RA

Herbal medicine has emerged as a promising complementary approach in the management of rheumatoid arthritis due to its multi-targeted therapeutic potential and comparatively favorable safety profile. Plant-based remedies have been used for centuries in traditional systems of medicine to alleviate joint pain and inflammation, and recent scientific investigations have supported their potential role in chronic inflammatory disorders. Herbal anti-arthritic agents are rich in bioactive constituents such as flavonoids, alkaloids, terpenoids, and phenolic compounds, which exhibit anti-inflammatory, antioxidant, and immunomodulatory properties. These compounds act on multiple molecular targets, including pro-inflammatory cytokines, oxidative stress pathways, and key signaling mechanisms involved in disease progression. Unlike synthetic drugs that often focus on a single target, herbal therapies tend to produce a broader therapeutic effect through synergistic actions of various phytochemicals.

In preclinical studies, several plant extracts have demonstrated significant reduction in inflammation, joint swelling, and tissue damage in experimental models of rheumatoid arthritis. Additionally, herbal medicines are generally associated with fewer side effects when used appropriately, making them attractive candidates for long-term management. Despite these advantages, challenges such as lack of standardization, variability in composition, and limited clinical evidence remain significant barriers to their widespread acceptance. Therefore, further research is required to validate their efficacy and ensure quality, safety, and consistency.

3.2 Important Medicinal Plants with Anti-Arthritic Activity



Fig 2: *Abelmoschus ficulneus*, *Uncaria tomentosa*, *Withania somnifera*, *Curcuma longa*

3.3 Phytoconstituents Responsible for Activity

The therapeutic potential of herbal anti-arthritic agents is largely attributed to the presence of diverse bioactive phytoconstituents. These compounds act through multiple mechanisms to reduce inflammation, modulate immune responses, and protect joint tissues. Among them, flavonoids, alkaloids, terpenoids, and phenolic compounds play a major role.

a) Flavonoids

Flavonoids are widely distributed plant polyphenols known for their strong anti-inflammatory and antioxidant properties. They help reduce oxidative stress by scavenging free radicals and inhibit the production of pro-inflammatory cytokines such as TNF-α and IL-6. Flavonoids also suppress key signaling pathways like NF-κB, thereby limiting inflammation and joint damage.

b) Alkaloids

Alkaloids are nitrogen-containing compounds that exhibit significant immunomodulatory and anti-inflammatory effects. They can regulate immune cell activity and reduce the release of inflammatory mediators. Some alkaloids also show analgesic properties, contributing to pain relief in arthritic conditions.

c) Terpenoids

Terpenoids are a large class of natural compounds with potent anti-inflammatory activity. They act by inhibiting enzymes such as cyclooxygenase (COX) and lipoxygenase (LOX), which are involved in the synthesis of inflammatory mediators. Terpenoids also help in reducing edema and preventing cartilage degradation.

d) Phenolic Compounds

Phenolic compounds, including phenolic acids and tannins, are known for their antioxidant and anti-inflammatory actions. They neutralize reactive oxygen species and protect tissues from oxidative damage. Additionally, phenolics can modulate inflammatory signaling pathways and enhance the body's defense mechanisms.

Table 2: Mechanisms of Action of Herbal Agents

Mechanism	Description	Therapeutic Outcome in RA
Anti-inflammatory activity	Herbal compounds suppress the production of inflammatory mediators such as prostaglandins, leukotrienes, and pro-inflammatory cytokines by inhibiting enzymes like COX and LOX.	Reduces joint swelling, pain, and inflammation
Immunomodulatory effects	Plant-derived constituents regulate immune cell activity, including T-cells, B-cells, and macrophages, helping to balance overactive immune responses.	Prevents autoimmune reactions and slows disease progression
Antioxidant mechanisms	Phytochemicals neutralize reactive oxygen species (ROS) and enhance endogenous antioxidant defenses such as superoxide dismutase and catalase.	Protects joint tissues from oxidative damage and reduces inflammation
Inhibition of NF-κB and cytokines	Herbal agents block activation of NF-κB signaling pathway and decrease the release of key cytokines like TNF-α, IL-1β, and IL-6.	Suppresses chronic inflammation and prevents cartilage and bone destruction

4. Preclinical Models Used in RA Research

- Freund's Complete Adjuvant (FCA)-induced arthritis
- Collagen-Induced Arthritis (CIA) model
- Evaluation parameters (paw edema, cytokines, histopathology)

Table 3: Comparative Analysis: Herbal vs Synthetic Agents

Parameter	Herbal Agents	Synthetic Agents
Mechanism-based comparison	Act on multiple targets simultaneously (cytokines, oxidative stress, immune pathways) due to diverse phytoconstituents	Act on specific molecular targets (COX enzymes, cytokines, immune receptors) with well-defined mechanisms
Efficacy in preclinical studies	Show significant reduction in inflammation and joint damage in models like FCA and CIA; effects may vary depending on extract and dose	Demonstrate strong and consistent efficacy with rapid action in reducing inflammation and disease progression
Safety and toxicity profile	Generally safer with fewer side effects when used appropriately; lower risk of severe toxicity	Associated with notable adverse effects such as gastrointestinal, hepatic, renal, and immunosuppressive complications
Cost-effectiveness	Usually cost-effective and widely accessible, especially in developing regions	Often expensive, particularly biologics; requires monitoring and long-term financial burden

5. Advantages and Limitations of Herbal Therapy

5.1 Benefits of natural origin

Herbal therapies offer several advantages in the management of rheumatoid arthritis due to their natural origin and diverse biological activities. One of the key benefits is their multi-targeted mechanism of action, as plant extracts contain a variety of bioactive compounds that act simultaneously on inflammatory pathways, immune responses, and oxidative stress. This broad spectrum of activity can provide balanced therapeutic effects.

Another important advantage is their relatively favorable safety profile. When used appropriately, herbal medicines are generally associated with fewer and less severe adverse effects compared to synthetic drugs, making them suitable for long-term use in chronic conditions like rheumatoid arthritis. Herbal agents are also rich in antioxidants and anti-inflammatory constituents, which help in reducing oxidative damage and controlling inflammation. In addition, many herbal medicines are cost-effective and easily accessible, particularly in developing countries where traditional medicine systems are widely practiced.

5.2 Variability and standardization issues

One of the major challenges associated with herbal therapy is the variability in composition and lack of proper standardization. Unlike synthetic drugs, which contain defined and consistent amounts of active ingredients, herbal preparations may show significant variation due to differences in plant species, geographical origin, harvesting time, and processing methods. These factors can influence the concentration and activity of bioactive constituents, leading to inconsistent therapeutic outcomes. In addition, the absence of uniform quality control measures makes it difficult to ensure batch-to-batch consistency. Variability in extraction techniques, solvent systems, and storage conditions can further affect the stability and potency of herbal products. Adulteration, contamination with heavy metals, pesticides, or microbial impurities also remains a concern in some preparations.

Another limitation is the lack of standardized dosing guidelines, which complicates the determination of safe and effective therapeutic doses. Without proper standardization, reproducibility of results in both preclinical and clinical studies become challenging. The development of validated quality control protocols, standardization of extracts based on active markers, and adherence to good manufacturing practices are essential to ensure the safety, efficacy, and reliability of herbal therapies in rheumatoid arthritis.

5.3 Lack of clinical validation

Despite promising results in preclinical studies, the clinical validation of herbal therapies in rheumatoid arthritis remains limited. Most evidence supporting their efficacy is derived from in vitro experiments and animal models, which may not fully replicate the complexity of human disease. As a result, translating these findings into reliable clinical outcomes is challenging.

A major limitation is the scarcity of well-designed clinical trials. Many available studies involve small sample sizes, lack proper control groups, or have short durations, making it difficult to draw definitive conclusions regarding safety and effectiveness. In addition, variability in herbal formulations and dosing regimens further complicates the comparison of results across different studies.

Another concern is the insufficient documentation of pharmacokinetics, herb–drug interactions, and long-term safety profiles. Since patients with rheumatoid arthritis often receive multiple medications, the potential for interactions between herbal and conventional drugs cannot be overlooked. Large-scale, randomized, and controlled clinical trials are essential to establish the therapeutic value of herbal medicines. Standardized formulations, clear dosing guidelines, and rigorous evaluation methods are necessary to improve their acceptance in evidence-based clinical practice.

6. Future Perspectives and Research Gaps

6.1 Need for clinical trials

Although herbal anti-arthritic agents have demonstrated encouraging results in preclinical studies, robust clinical evidence is essential to confirm their safety and therapeutic effectiveness in humans. Clinical trials play a critical role in translating experimental findings into evidence-based medical practice by evaluating efficacy under controlled conditions.

Well-designed randomized controlled trials are required to determine optimal dosing, treatment duration, and long-term outcomes of herbal therapies in rheumatoid arthritis. Such studies help establish clear cause–effect relationships, minimize bias, and provide

reliable data on clinical benefits and potential risks. Clinical trials are also necessary to assess safety profiles, including possible adverse effects and interactions with conventional drugs commonly used in rheumatoid arthritis management. This is particularly important as many patients use herbal medicines alongside standard therapies. Standardized formulations and validated biomarkers should be incorporated into clinical studies to ensure consistency and reproducibility of results. Generating high-quality clinical evidence will enhance the credibility of herbal medicine and support its integration into modern therapeutic strategies for rheumatoid arthritis.

6.2 Standardization of herbal extracts

Standardization of herbal extracts is essential to ensure consistent quality, safety, and therapeutic efficacy. Unlike synthetic drugs, herbal preparations contain multiple bioactive constituents whose concentrations can vary depending on factors such as plant source, harvesting conditions, and extraction methods. Standardization aims to minimize this variability and produce reproducible formulations with defined chemical profiles.

A key aspect of standardization involves the identification and quantification of marker compounds that are responsible for biological activity. Analytical techniques such as chromatography and spectrophotometry are commonly used to establish quality control parameters, including purity, potency, and stability. In addition, standardization requires proper selection of plant material, authentication of species, and control of cultivation and processing conditions.

Another important component is the development of uniform extraction procedures and dosage forms to maintain batch-to-batch consistency. Ensuring the absence of contaminants such as heavy metals, pesticides, and microbial impurities is also crucial for product safety. standardization enhances the reliability of herbal medicines, facilitates comparison across studies, and supports their acceptance in clinical practice by aligning them with modern pharmaceutical quality standards.

6.3 Combination therapy approaches

Combination therapy represents a promising strategy in the management of rheumatoid arthritis by integrating herbal agents with conventional synthetic drugs. This approach aims to enhance therapeutic efficacy while minimizing adverse effects associated with long-term use of synthetic medications.

Herbal compounds, with their multi-targeted mechanisms, can complement the action of synthetic drugs that typically focus on specific pathways. For example, while synthetic agents suppress key inflammatory mediators, herbal constituents may simultaneously provide antioxidant protection and immunomodulatory effects. This synergistic interaction can improve overall disease control and may allow for dose reduction of conventional drugs, thereby decreasing toxicity. In addition, combination therapy may help in overcoming limitations such as drug resistance or incomplete response observed with monotherapy. Preclinical studies have indicated that certain plant extracts, when used alongside standard drugs, can enhance anti-inflammatory effects and reduce joint damage more effectively than either treatment alone.

However, careful consideration is required due to the potential for herb–drug interactions, which may alter drug metabolism or therapeutic outcomes. Therefore, well-designed clinical studies and proper monitoring are essential to ensure the safety and effectiveness of such combined approaches.

6.4 Novel drug delivery systems

Novel drug delivery systems have gained significant attention in the management of rheumatoid arthritis to improve the efficacy, stability, and targeted delivery of both herbal and synthetic anti-arthritic agents. Conventional dosage forms often suffer from limitations such as poor bioavailability, rapid degradation, and systemic side effects. Advanced delivery systems are designed to overcome these challenges and enhance therapeutic outcomes.

Various nanocarrier-based systems, including liposomes, niosomes, nanoparticles, and nanoemulsions, are widely explored for targeted drug delivery to inflamed joint tissues. These systems can improve drug solubility, prolong circulation time, and enable controlled or sustained release of active compounds. In the case of herbal drugs, novel carriers help protect sensitive phytoconstituents from degradation and enhance their absorption. Targeted delivery approaches, such as ligand-mediated systems and stimuli-responsive carriers, allow drugs to accumulate specifically at inflamed sites, reducing off-target effects and improving therapeutic efficiency. Transdermal and topical delivery systems, including gels and patches, are also being developed to provide localized action and reduce systemic exposure.

Despite their potential advantages, challenges such as formulation complexity, scalability, cost, and regulatory approval remain barriers to widespread application. Continued research and technological advancements are necessary to optimize these systems and translate them into clinical practice for effective rheumatoid arthritis management.

7. Conclusion

Rheumatoid arthritis is a complex autoimmune disorder characterized by chronic inflammation, immune dysregulation, and progressive joint damage. Conventional synthetic therapies, including NSAIDs, corticosteroids, and DMARDs, remain the mainstay of treatment due to their proven efficacy in controlling disease activity and preventing structural damage. However, their long-term use is often limited by adverse effects, high cost, and the need for continuous monitoring.

Herbal anti-arthritic agents have emerged as promising alternatives or adjunct therapies due to their multi-targeted mechanisms, including anti-inflammatory, antioxidant, and immunomodulatory actions. Preclinical studies have demonstrated that several plant-derived compounds can effectively reduce inflammation and protect joint integrity, often with a comparatively better safety profile. Additionally, advancements in novel drug delivery systems and combination therapy approaches have further enhanced the therapeutic potential of herbal medicines.

Despite these encouraging findings, challenges such as variability in composition, lack of standardization, and limited clinical validation continue to restrict their widespread acceptance. Therefore, rigorous scientific evaluation through well-designed clinical trials and standardized formulations is essential to establish their safety and efficacy.

In conclusion, a balanced integration of herbal and synthetic therapies, supported by modern research and technological advancements, holds significant promise for developing safer, more effective, and patient-friendly treatment strategies for rheumatoid arthritis.

REFERENCES

1. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388:2023–2038.
2. Firestein GS, McInnes IB. Immunopathogenesis of rheumatoid arthritis. Immunity. 2017;46:183–196.
3. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet. 2010;376:1094–1108.
4. McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. Nature. 2011;473:227–234.
5. Choy EH, Panayi GS. Cytokine pathways in rheumatoid arthritis. N Engl J Med. 2001;344:907–916.
6. Feldmann M, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol. 2008;26:237–259.
7. Singh JA, Saag KG, Bridges SL. 2015 ACR guideline for RA treatment. Arthritis Rheumatol. 2016;68:1–26.
8. Burmester GR, Pope JE. Novel treatment strategies in RA. Lancet. 2017;389:2338–2348.
9. Crofford LJ. Use of NSAIDs in treating RA. Arthritis Res Ther. 2013;15:S2.
10. Buttgereit F, Burmester GR, Lipworth BJ. Optimized glucocorticoid therapy. Lancet. 2005;365:801–803.
11. Cronstein BN. Low-dose methotrexate mechanisms. Arthritis Res Ther. 2005;7:234–239.
12. Smolen JS, Landewé R, Bijlsma J. EULAR recommendations for RA. Ann Rheum Dis. 2020;79:685–699.
13. Tanaka Y. Biologic therapies in RA. Immunol Rev. 2016;269:1–12.
14. Scott IC, Kingsley GH, Scott DL. Biologic DMARDs safety. Rheumatology. 2011; 50:169–175.
15. Schett G, Gravallese E. Bone erosion in RA. Nat Rev Rheumatol. 2012;8:656–664.
16. Gupta SC, Patchva S, Aggarwal BB. Therapeutic roles of curcumin. AAPS J. 2013;15:195–218.
17. Singh N, Bhalla M, Jager PD. Withania somnifera overview. Altern Med Rev. 2011;16:306–313.
18. Sandoval M, Okuhama NN, Zhang XJ. Anti-inflammatory activity of Uncaria tomentosa. J Ethnopharmacol. 2000;72:81–87.
19. Pan MH, Lai CS, Ho CT. Anti-inflammatory activity of natural compounds. J Agric Food Chem. 2010;58:667–672.
20. Middleton E, Kandaswami C, Theoharides TC. Effects of flavonoids. Pharmacol Rev. 2000;52:673–751.
21. Rahman I. Oxidative stress in inflammation. Free Radic Biol Med. 2006;40:125–136.
22. Mittal M, Siddiqui MR, Tran K. Reactive oxygen species in inflammation. Antioxid Redox Signal. 2014;20:1126–1167.
23. Lawrence T. NF-κB pathway in inflammation. Cold Spring Harb Perspect Biol. 2009;1:a001651.
24. Barnes PJ. Anti-inflammatory actions of glucocorticoids. Clin Sci. 1998;94:557–572.
25. Aggarwal BB, Harikumar KB. Potential of curcumin. Int J Biochem Cell Biol. 2009;41:40–59.
26. Patra JK, Das G, Fraceto LF. Nano-based drug delivery systems. J Nanobiotechnology. 2018;16:71.
27. Zhang L, Gu FX, Chan JM. Nanoparticles in drug delivery. Clin Pharmacol Ther. 2008;83:761–769.
28. Peer D, Karp JM, Hong S. Nanocarriers in medicine. Nat Nanotechnol. 2007;2:751–760.
29. Zhao Y, Wu C, Zhang X. Smart nanocarriers in inflammatory diseases. Acta Pharm Sin B. 2022;12:450–466.
30. Torchilin VP. Multifunctional nanocarriers. Nat Rev Drug Discov. 2014;13:813–827.
31. Tilburt JC, Kaptchuk TJ. Herbal medicine research challenges. BMJ. 2008;337:a245.

32. Ekor M. Herbal medicine safety issues. Front Pharmacol. 2014;4:177.
33. Heinrich M, Barnes J, Gibbons S. Fundamentals of pharmacognosy. 2nd ed. Elsevier; 2012.
34. Wagner H. Synergy research in phytomedicine. Phytomedicine. 2011;18:123–126.
35. Williamson EM. Synergy and herbal medicines. Phytomedicine. 2001;8:401–409.

How to cite this article:
Miss. Shivani Tiwari et al. Ijppr.Human, 2026; Vol. 32 (5): 155-165.
Conflict of Interest Statement: All authors have nothing else to disclose.